EpiEndo Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- EpiEndo Pharmaceuticals's estimated annual revenue is currently $4.6M per year.
- EpiEndo Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- EpiEndo Pharmaceuticals has 23 Employees.
EpiEndo Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Strategic Advisor | Reveal Email/Phone |
EpiEndo Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is EpiEndo Pharmaceuticals?
EpiEndo Pharmaceuticals is an Icelandic pharmaceutical company focused on Chronic Airway Diseases. EpiEndo was founded in 2014.
keywords:N/AN/A
Total Funding
23
Number of Employees
$4.6M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
EpiEndo Pharmaceuticals News
2022-04-06 - Robotics Startup Galen Snags Moderna Legend Robert Langer
At the Swedish American Life Sciences Summit, he was on a panel that awarded EpiEndo Pharmaceuticals the Rising Star Award.
2022-03-22 - Appointments and advancements for March 24, 2022
Epiendo Pharmaceuticals ehf, of Reykjavik, Iceland, appointed Stefan Petursson chief financial officer, effective April 1.
2022-03-22 - EpiEndo Pharmaceuticals Expands its Leadership Team, Appointing ...
EpiEndo Pharmaceuticals Expands its Leadership Team, Appointing Stefan Petursson as Chief Financial Officer to Support Future Growth.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.5M | 26 | N/A | N/A |
#2 | $6.3M | 31 | 3% | N/A |
#3 | $6.1M | 31 | 11% | N/A |
#4 | $10.3M | 40 | N/A | N/A |
#5 | $8.3M | 41 | N/A | N/A |